Apnea of prematurity is a common condition that is usually treated with methylxanthines. Methylxanthines are adenosine receptor blockers that have powerful influences on the central nervous system. However, little is known about the long-term effects of methylxanthines on the developing brain. In particular, it is not known whether methylxanthines have permanent adverse effects on sleep architecture and ventilatory control, resulting in an increased prevalence of sleep disorders such as insomnia and the obstructive sleep apnea syndrome (OSAS). Children who were born prematurely are at increased risk for neurobehavioral abnormalities. It is possible that these neurologic comorbidities are mediated, in part, through sleep disturbances that may result from methylxanthine exposure. This research proposal will take advantage of a unique cohort of ex-premature, 5-6 year old children who were randomized at birth to receive either caffeine or placebo, and are currently receiving detailed neurocognitive and behavioral assessments (the Caffeine for Apnea of Prematurity [CAP] trial). There is a time-based urgency to performing this study, as follow-up of the CAP cohort is in progress, and neurobehavioral assessments need to be performed in close proximity to the sleep assessments. The overall hypothesis is that methylxanthine use in preterm infants, while beneficial in the short term, results in longstanding abnormalities in the regulation of sleep, and breathing during sleep.
In Aim 1, we will determine the long-term effects of methylxanthine administration on sleep/wake patterns. Specifically, we will use actigraphy, sleep diaries and questionnaires to measure sleep in ex-premature 5-6 year old children who received either caffeine or placebo during the neonatal period. We hypothesize that children who received caffeine will have decreased sleep time, and increased prevalence of difficulties falling asleep and staying asleep, compared to controls.
In Aim 2, we will determine the long-term effects of methylxanthine administration on the prevalence of OSAS during childhood. Specifically, we will use ambulatory polysomnography to characterize breathing during sleep in ex-premature 5-6 year old children who received either caffeine or placebo during the neonatal period. We hypothesize that children who received caffeine will have an increased prevalence of OSAS.
In Aim 3, we will determine the contribution of sleep disruption, OSAS and methylxanthine administration to neurocognitive and behavioral abnormalities in ex-premature children. Specifically, we will determine the relationship between sleep time, OSAS and neurobehavioral measures (being obtained through the parent study) in ex-premature 5-6 year old children who received either caffeine or placebo during the neonatal period. We hypothesize that sleep disruption and OSAS will contribute to neurocognitive and behavioral abnormalities. These studies will help determine the long-term consequences of neonatal methylxanthine therapy, ultimately resulting in improved management of apnea of prematurity.

Public Health Relevance

Methylxanthines are used often in the neonatal intensive care unit to treat premature infants with apnea of prematurity. However, the long-term consequences of these drugs are unknown. This study will determine whether neonatal methylxanthine treatment results in long-term perturbations in sleep, breathing during sleep, and hence, neurocognitive and behavioral abnormalities.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL098045-03
Application #
8120256
Study Section
Special Emphasis Panel (ZHL1-CSR-G (M1))
Program Officer
Lewin, Daniel S
Project Start
2009-09-01
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
3
Fiscal Year
2011
Total Cost
$282,648
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Cielo, Christopher M; DelRosso, Lourdes M; Tapia, Ignacio E et al. (2017) Periodic limb movements and restless legs syndrome in children with a history of prematurity. Sleep Med 30:77-81
Biggs, Sarah N; Meltzer, Lisa J; Tapia, Ignacio E et al. (2016) Sleep/Wake Patterns and Parental Perceptions of Sleep in Children Born Preterm. J Clin Sleep Med 12:711-7
Tapia, Ignacio E; Shults, Justine; Doyle, Lex W et al. (2016) Perinatal Risk Factors Associated with the Obstructive Sleep Apnea Syndrome in School-Aged Children Born Preterm. Sleep 39:737-42
Meltzer, Lisa J; Wong, Petrina; Biggs, Sarah N et al. (2016) Validation of Actigraphy in Middle Childhood. Sleep 39:1219-24
Marcus, Carole L; Meltzer, Lisa J; Roberts, Robin S et al. (2014) Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. Am J Respir Crit Care Med 190:791-9
Marcus, Carole L; Traylor, Joel; Biggs, Sarah N et al. (2014) Feasibility of comprehensive, unattended ambulatory polysomnography in school-aged children. J Clin Sleep Med 10:913-8